T cell engagers are an exciting area of immunotherapy that remains in the early innings of development. We believe gamma-delta T cells offer unique properties, including tissue residence, phagocytosis ...

Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a provider of consumer health care and lifestyle products, is announcing its financial results for the three and twelve months ended ...

Rapid7 recently announced significant updates to its global PACT partner program, uniting and energizing partners with tailored engagement programs and specializations, an all-new Partner Training ...

WILMETTE, Ill., March 31, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with ...

Shirofune, the leading automated digital advertising management platform that services major advertising agencies worldwide ...

TORONTO, ON / ACCESS Newswire / March 31, 2025 / abrdn Asia-Pacific Income Fund VCC (TSX:FAP)(UEN:T21VC0235H) (the "Company"), a ...

MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease (AKD); Initial Data Expected in Q1 2026MZE782 Phase 1 Healthy Volunteer ...

Net Income Rises 14.7% Year-Over-Year on Increased Gross Margin, Efficient OperationsProvides Initial 2025 Outlook for Further 10% Growth in ...

On May 21, 2024, the Company announced that the U.S. Food and Drug Administration (FDA) provided clearance for the Company’s investigational new drug (IND) application to proceed with a Phase 1 ...

Reiterates 2025 guidance of $80 million to $90 million in revenue and mid-40s percentage gross margin - SAN DIEGO, CA, March 31, 2025 (GLOBE ...

CHICAGO, March 31, 2025 (GLOBE NEWSWIRE) -- Pando, the leading supply chain AI company, has been recognized by Gartner as a Visionary in the 2025 Magic Quadrant for Transportation Management Systems.

Announced the acceptance of the New Drug Application (NDA) by the U.S. Food and Drug Administration (FDA) for OLC for the treatment of hyperphosphatemia in patients with CKD on dialysis. The FDA set a ...